REN and Hyperkalemia: In general, the current evidence suggests that sacubitril/valsartan does not convincingly lead to an absolute reduction in the risk of renal dysfunction and hyperkalemia, although it may result in a slower rate of decrease in eGFR compared to inhibition of the renin-angiotensin system alone.